🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,931 results for “The” Clear

  1. Infigratinib

    BridgeBio Oncology Therapeutics

    Hypochondroplasia

    phase 2 small molecule active

    1 trial

  2. Infigratinib 0.016 mg/kg

    BridgeBio Oncology Therapeutics

    Achondroplasia

    phase 2 small molecule completed

    1 trial

  3. Infigratinib is provided as a single dose of minitablets for oral administration

    BridgeBio Oncology Therapeutics

    Achondroplasia

    phase 2 small molecule active

    1 trial

  4. Inhaled Treprostinil

    United Therapeutics Europe Ltd

    Sarcoidosis

    phase 2 small molecule completed

    1 trial

  5. Inhaled Treprostinil (Tyvaso Nebulizer)

    United Therapeutics Europe Ltd

    COPD (Chronic Obstructive Pulmonary Disease)

    phase 2 small molecule active

    1 trial

  6. Inotuzumab Ozogamicin±Donor Lymphocyte Infusion

    The First People's Hospital of Lianyungang

    Leukemia, Lymphocytic, Acute

    phase 2 small molecule active

    1 trial

  7. Insulin

    United Therapeutics Europe Ltd

    Acute Stroke

    phase 2 small molecule completed

    1 trial

  8. Insulin

    United Therapeutics Europe Ltd

    Multiple Sclerosis, Relapsing-Remitting

    phase 2 small molecule completed

    1 trial

  9. Insulin lispro

    HALOZYME THERAPEUTICS, INC.

    Diabetes Mellitus, Type II

    phase 2 small molecule completed

    1 trial

  10. Insulin lispro

    HALOZYME THERAPEUTICS, INC.

    Diabetes Mellitus, Type 1

    phase 2 small molecule completed

    2 trials

  11. Intensity-modulated radiation therapy (IMRT) in combination with fluzoparib, abiraterone acetate tablets (II), and prednisone.

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Metastatic Castration-resistant Prostate Cancer

    phase 2 small molecule active

    1 trial

  12. Intensive Intraperitoneal Therapy in Advanced Ovarian Cancer

    The George Institute

    Ovarian Cancer

    phase 2 other active

    1 trial

  13. Interferon Beta-1B

    The University of Hong Kong

    COVID

    phase 2 small molecule completed

    1 trial

  14. Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T cells

    The First People's Hospital of Lianyungang

    B Cell Lymphoma

    phase 2 mab active

    1 trial

  15. Intracavernosal administration of autologous ADRC

    The First People's Hospital of Lianyungang

    Erectile Dysfunction

    phase 2 other completed

    1 trial

  16. Intranasal Oxytocin

    United Therapeutics Europe Ltd

    Autism Spectrum Disorder

    phase 2 small molecule completed

    1 trial

  17. Intrathecal Administration of Thiotepa in Combination with Trastuzumab via the Ommaya Reservoir

    The First People's Hospital of Lianyungang

    Leptomeningeal Metastasis of HER2-positive Breast Cancer

    phase 2 small molecule active

    1 trial

  18. Intravenous esketamine using Dixon's up-and-down sequential method

    The First People's Hospital of Lianyungang

    Hepatic Neoplasm

    phase 2 small molecule active

    1 trial

  19. Iodine-124

    United Therapeutics Europe Ltd

    Thyroid Cancer

    phase 2 small molecule active

    1 trial

  20. Iparomlimab and Tuvonralimab Injection (QL1706)

    The First People's Hospital of Lianyungang

    Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  21. Iparomlimab and Tuvonralimab Injection in combination with TFOX

    The First People's Hospital of Lianyungang

    Gastric or Gastroesophageal Junction Adenocarcinoma

    phase 2 small molecule active

    1 trial

  22. Iparomlimab and Tuvonralimab combined with lenvatinib and SOX

    The First People's Hospital of Lianyungang

    Gastric or Gastroesophageal Junction Adenocarcinoma

    phase 2 small molecule active

    1 trial

  23. Iparomlimab/Tuvonralimab

    The First People's Hospital of Lianyungang

    Recurrent Ovarian Cancer

    phase 2 small molecule active

    1 trial

  24. Ipilimumab

    United Therapeutics Europe Ltd

    Locally Advanced Clear Cell Renal Cell Carcinoma

    phase 2 mab active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources